Trial Profile
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 04 Apr 2023 Planned End Date changed from 1 Mar 2024 to 30 Sep 2024.
- 04 Apr 2023 Planned primary completion date changed from 1 Mar 2024 to 30 Sep 2024.
- 03 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.